Compare iShares MSCI Germany (DAX) (EWG) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Summit Therapeutics Inc — how do they compare? iShares MSCI Germany (DAX) trades at $40.98 (market cap $1.42B), while Summit Therapeutics Inc trades at $17.48 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 9.7× iShares MSCI Germany (DAX)'s market cap, and Summit Therapeutics Inc is more actively traded (6,173,057 versus 1,110,573). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 54 Days and Summit Therapeutics Inc for 16 Days on average.
| EWG | SMMT | |
|---|---|---|
Market Cap | $1.42B | $13.71B |
Volume | 1,110,573 | 6,173,057 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $26.38 |
52-Week Low | $38.08 | $12.43 |
Typical Hold Time | 54 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $40.91, down 1.4% with a bearish technical outlook showing 19 sell signals versus 1 buy. The stock faces resistance at $41 with support at $40. Technical indicators show oversold conditions with RSI at 25.94, but moving averages and oscillators remain bearish. Recent European market sentiment is mixed with ECB rate hikes and energy price concerns affecting regional equities.
Investment outlook remains cautious given the bearish technical signals and macroeconomic pressures from ECB tightening. The stock's proximity to support levels suggests potential for near-term stabilization, but sustained recovery requires improved fundamental performance and easing of European economic concerns.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
